painless endoscopy
Conditions
Interventions
A:Alfentanil 5 µg/kg was slowly injected intravenously for more than 10 s. After 30 s, ciprofol was injected intravenously
B:Alfentanil 7 µg/kg was slowly injected intravenously for more than 10 s. After 30 s, ciprofol was injected intravenously
C:Alfentanil 10 µg/kg was slowly injected intravenously for more than 10 s. After 30 s, ciprofol was injected intravenously
Sponsors
The Affiliated Suzhou Hospital of Nanjing Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1) patients undergoing elective painless gastroscopy or colonoscopy 2) Age of 18-60 years old, both sexes 3) BMI : 18.5-28 kg/m2 4) American Society of Anesthesiologists (ASA) grade I-II 5) The operation time should be within 45 minutes 6) The subjects voluntarily participated in the trial and signed the informed consent for this trial
Exclusion criteria
Exclusion criteria: 1) The subjects explicitly refused to participate in the study 2) allergy to opioids, benzodiazepines, cyclopropofol, flumazenil or naloxone 3) use of ß-blockers, anxiolytics and antidepressants 4) suspected abuse of narcotic analgesics or sedatives, and alcohol abuse 5) ECG: heart rate 100 beats /min, or severe arrhythmia 6) a history of acute respiratory infection without cure within 2 weeks 7) patients with a history of serious heart, brain, lung, liver, kidney or metabolic diseases, neuromuscular diseases (such as myasthenia gravis), or psychiatric diseases 8) systolic blood pressure >180 mmHg and/or diastolic blood pressure >110 mmHg in patients with hypertension, or <90/60 mmHg in patients with hypotension 9) patients with a history of gastrointestinal diversion 10) patients with a history of abnormal anesthesia recovery 11) predicted that difficult airway might occur or had occurred in the past, such as modified Maanobis classification ?-? 12) pregnant or lactating women and patients (including men) who plan to have children within 3 months 13) other subjects who were deemed by the investigators to be inappropriate to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SpO2;respiratory rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| NBP;heart rate;Ciprofol add times;Ciprofol dosage; | — |
Countries
CHINA
Contacts
Public ContactGu Chengyong
The Affiliated Suzhou Hospital of Nanjing Medical University
Outcome results
None listed